共 50 条
- [1] Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center, open-label, single-arm, phase II studyCANCER RESEARCH, 2024, 84 (09)Peng, PeiJianXu, Xiao-LuZhong, Jin-CaiYe, Jin-HuiWang, Zhi-HuiWang, HongLin, HongDu, Cai-WenZou, GuorongOuyang, JieShi, Ying-YingXu, FeiYu, Geng-ShengLu, Yong-KuiWang, Yong-XiaCui, Shi-EnLi, Lu-Zhen
- [2] Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Peng, PeijianXu, XiaoluZhong, JincaiYe, Jin-HuiWang, Zhi-HuiWang, HongLin, HongDu, CaiwenZou, GuorongOuyang, JieShi, Ying-yingXu, FeiYu, GengshengLu, YongkuiWang, Yong-XiaCui, Shi-EnLi, Lu-Zhen
- [3] Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II studyBMC CANCER, 2024, 24 (01)Cheng, YuTeng, ZanZhang, YanqiaoJin, BoZheng, ZhendongMan, LiWang, ZhenghuaTeng, YueeYu, PingShi, JingLuo, YingWang, YingZhang, JingdongZhang, HuijuanLiu, JiweiChen, HaoXiao, JiawenZhao, LeiZhang, LingyunJiang, YuChen, YingZhang, JianWang, ChangLiu, SaQu, JingleiQu, XiujuanLiu, Yunpeng
- [4] Safety and efficacy of eribulin as second-line treatment for HER2-negative metastatic breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Michalaki, VasilikiPsychogios, JohnContis, JohnKondi, AgathiGennatas, ConstantinePapadimitriou, Christos A.Vasiliou, John
- [5] Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II studyANNALS OF ONCOLOGY, 2022, 33 (07) : S648 - S649Yin, Y.Wu, X.Huang, X.Li, W.Hua, Y.Liang, Y.
- [6] Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Yin, YongmeiWu, XinyuHua, YijiaSun, ChunxiaoLiang, YanYang, FanHuang, XiangLi, Wei
- [7] Pembrolizumab plus eribulin in hormone receptore-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trialEUROPEAN JOURNAL OF CANCER, 2021, 148 : 382 - 394Perez-Garcia, Jose M.Llombart-Cussac, AntonioCortes, Maria G.Curigliano, GiuseppeLopez-Miranda, ElenaAlonso, Jose L.Bermejo, BegonaCalvo, LourdesCaranana, Vicentede la Cruz Sanchez, SusanaVazquez, Raul M.Prat, AleixBorrego, Manuel R.Sampayo-Cordero, MiguelSegui-Palmer, Miguel A.Soberino, JesusMalfettone, AndreaSchmid, PeterCortes, Javier
- [8] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomesCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 923 - 933Kimura, KoseiIwamoto, MitsuhikoTanaka, SatoruYamamoto, DaigoYoshidome, KatsuhideOgura, HiroyukiTerasawa, RisaMatsunami, NobukiTakahashi, YukoNitta, ToshikatsuMorimoto, TakashiFujioka, HiroyaKawaguchi, KanakoUchiyama, Kazuhisa
- [9] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomesCancer Chemotherapy and Pharmacology, 2018, 81 : 923 - 933Kosei KimuraMitsuhiko IwamotoSatoru TanakaDaigo YamamotoKatsuhide YoshidomeHiroyuki OguraRisa TerasawaNobuki MatsunamiYuko TakahashiToshikatsu NittaTakashi MorimotoHiroya FujiokaKanako KawaguchiKazuhisa Uchiyama
- [10] An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal CancerCLINICAL COLORECTAL CANCER, 2011, 10 (03) : 171 - 177Cohn, Allen L.Shumaker, Grace C.Khandelwal, PankajSmith, David A.Neubauer, Marcus A.Mehta, NileshRichards, DonaldWatkins, David L.Zhang, KathyYassine, Mohamed R.